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Abstract
Coronavirus disease (COVID-19) caused by infection of SARS-
CoV-2 as of May 2020 has been confirmed in more than 3 million 
people, with more than 200 thousands deaths across the globe. 
It has been known that COVID-19 patients with underlying 
cardiovascular diseases and its risks including: hypertension, 
diabetes, coronary artery disease, and cerebrovascular diseases, 
may develop more severe respiratory track symptoms and 
requiring intensive care. Some patients may presenting with 
myocarditis or acute heart failure, which have high mortality 
and morbidity. There were evidences of myocardial Injury with 
an increase of troponin in one-third of those with COVID-19.  It 
is conceivable that among those who recover from COVID-19 
infection, there is a risk of developing cardiomyopathy in the 
future. Although there is no available study yet on chronic 
cardiac effects in COVID-19 survivors,  there are some possible 
mechanisms of cardiomyopathy development as the COVID-19 
sequelae. Optimal medical treatment especially during 
hospitalization and any comprehensive preventions should be 
taken to manage the risks of developing cardiomyopathy after 
discharge. These includes : providing best available COVID-19 
drugs, cardiovascular medications and treatments, and other 
social preventive measures. 
(Indonesian J Cardiol. 2020;41:120-124)
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Introduction
Coronavirus disease of 2019 (COVID-19) is caused by new strain of coronavirus named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1 The first 
case of COVID-19 was started in Wuhan, China, then 
rapidly spread all over the world.1 The World Health 
organization (WHO) have declared it as a pandemic. 
By May 2020 there were more than 4 millions people 
infected, with more than 250 thousands death reported 
across the globe.2 Many of those having severe symptoms 
were with underlying cardiovascular diseases or its risks 
such as: hypertension, diabetes, coronary artery diseases, 
and cerebrovacular diseases.1
Early reports on patients with COVID-19 revealed 
that cardiac injury with  elevated cardiac biomarkers, 
ECG changes, left ventricular dysfunction, including 
those described as cardiomyopathy  were found in 
in the range of 12% to 33% patients.1,3 Once those 
patients survive from the acute phase of infection, they 
may develop various extent of chronic cardiomyopathy. 
Recent recommendation on cardiovascular diseases 
and COVID-19 stated that pre-existing cardiovascular 
diseases may increase morbidity and mortality of patients 
with COVID-19, and warned that COVID-19 may 
cause serious cardiac sequelae. 4 reduced SARS-CoV-2 
in swab samples.4 Those combinations are known to 
prolong the QT interval and will increase the incident 
of Torsades de Pointes (TdP). The risk of TdP increases 
in critical patients, 
Cardiomyopathy is a catasthropic condition of 
the heart leading for congestive heart failure (CHF), 
which increase risk of future mortality and morbidity.4 
Since we are in the mid of pandemic, there was no 
study yet on chronic effect of current COVID-19 
for the development of cardiomypathy as sequelae. 
However we can learn from animal experimental in the 
past looking for cardiac sequela of coronavirus family 
infection focusing on development of cardiomyopathy.5 
It has also been known in human that viral infection 
such as coronavirus may result in myocarditis or heart 
dysfunction that lead to chronic cardiomyopathy as 
sequelae, once the patient survive. Along with recent 
findings on cardiac invovement following COVID-19, 
we may have insight on possible myocardial sequelae of 
those surviving from  the disease course .
Given the close association between COVID-19 
infection and myocardial injury, current review will 
highlight possible mechanisms and most importantly 
optimal management COVID-19 as well as other 
measures of prevention in order to reduce the extent of 
cardiomyopathy among the survivors. It is important to 
pay attention to this survivor population in the future, 
since they might be vulnerable of future events as well as 
chance of having re-infection. 
Mechanisms of cardiomyopathy following Coro-
navirus infection 
Study in the rabbit model of a coronavirus-induced 
dilated cardiomyopathy revealed that among animals 
that survive of coronavirus infection, there was an 
increase of heart mass, dilation of ventricle, myocite 
hyperthrophy, myocardial fibrosis, and myocarditis 
leading to development of dilated cardiomyopathy.5 
Development of ventricular dilation along with 
myocarditis and some degree of hypertrophy observed in 
all survivors with different degrees from mild to severe. 
Uniquely, there was more pronounced of Interstitial and 
replacement fibrosis in the papillary muscles.5 All those 
findings suggested that coronavirus infection survivors 
may develop cardiomyopathy with different extents 
after an acute episode of the infection. 
Coronavirus SARS-CoV-2 infected the host by 
attaching its protein spike at the surface of the virus to 
angiotensyn converting enzyme-2 (ACE-2) receptors. 
6 ACE-2 was found in the lung alveolar epithelium, 
pericytes, cardiomyocytes, and enterocytes in the small 
intestine.  Once the virus attached to the ACE-2 receptor 
at the lung alveolar, it then may cause pneumonia leading 
for acute severe acute respiratory distress syndrome as 
reported mostly during this pandemi.6
There were multiple possible mechanisms of cardiac 
injury leading to cardiomyopathy in COVID-19 as 
summarized at Figure 1: 6,7
- COVID-19 may result in myocardial injury due to
severe immune inflammatory response and cytokine
storm.8
- Acute respiratory damage leading to hypoxia
caused by pneumonia in COVID-19 could induce
oxidative stress as well as myocardial injury due to
increase of myocardial oxygen demand.
- Invasion of SARS-CoV-2 viral to the cardiomyocytes 
may causing direct toxic effect leading to
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myocarditis.9
- Infection with SARS-CoV-2 may trigger 
microvascular dysfunction via its effects on ACE-2 
receptor. This further causing tissue ischemia leading 
to ventricular dysfunction and/or arrhythmias.7
All those proposed mechanisms may result in 
myocardial fibrosis with various degree once the diseases 
recede. It may eventually cause cardiomyopathy sequelae 
with various clinical presentations.
Figure 1. Possible mechanisms of cardiomyopathy in 
COVID-19 
There was also a new term introduced as acute 
COVID-19 cardiovascular syndrome (AcovCS) in some 
patients presenting with myocarditis-like syndrome, 
that involving acute myocardial injury. It was associated 
with reduced left ventricular ejection fraction without 
evidence of obstructive coronary artery disease. This 
syndrome may be complicated with cardiac arrhythmias 
and/or clinical heart failure with or without associated 
hemodynamic instability including shock. 10
More or less the mechanisms may be similar with 
those shown in Figure 1. Recent clinical data from China 
and US revealed that heart failure and cardiomyopathy 
although more frequent in non-survivors may be also be 
found as the sequelae among the survivors.11 However, 
details on chronicity, type and class of heart failure In 
human with COVID-19 have not been consistently 
reported. Whether cases of cardiomyopathy exactly 
result from the underlying inflammatory state, hypoxia 
and hemodynamic impairment, or a direct effect of 
COVID-19, remains to be studied.11
 Assessment for Cardiomyopathy in COVID-19
To assess COVID-19 patients with possibility of 
having cardiomyopathy or potential for its development 
in the future, currently no special guidelines available. 
However basic and common cardiovascular assessment 
shoud be performed. A risk and benefit consideration 
of doing an examination in COVID-19 patients should 
always be put in first place. Safety precausios of medical 
workers and the patients must be done first. 
Once history and physical examinations were taken, 
further cardiac assesment would be required such as:
Electrocardiogram (ECG). Some COVID-19 patients 
may develop ECG changes ranging from ST elevation, 
ST depression, low voltage in the lim leads, and PVCs.12 
Although there is no specific changes for those with 
COVID-19, it is reasonable to incorporate the data 
with other examiantion and tests. For those with ECG 
changes along with other positive findings in other tests, 
thorough assessment and more intensive management 
may be required.
- Blood test. To assess cardiac involvement in 
COVID-19 patients laboratory testing for troponin 
and NT pro-BNP is required.12 The other essential 
tests especially for those requiring hospital care might 
be including: C-reactive protein (CRP), ferritin, D- 
dimer, IL-6, and LDH, which were known elevated 
as response to SARS-CoV-2. The presence of these 
inflammatory biomarkers are  associated with poor 
prognosis.13
- Echocardiography. Echocardiography can be 
useful to assess left and right ventricular structure 
and function, wall motion abnormalities, and to 
estimate cardiac hemodynamics. However, it is 
important to minimize sonographer time with 
COVID-19 positive patients to reduce the risk 
of spread. To this end, the decision to obtain an 
echocardiogram should be made on the basis of 
patient characteristics, blood test abnormalities, 
and hemodynamic stability and whether 
echocardiography information will make a 
difference in management.7
- Other modalities. To assess cardiac complication 
In center with capabilities, additional of doing 
more examination such as : cardiac magnetic 
resonance,  endomyocardial biopsy and/or cardiac 
catheterization might be required if really necessary 
with cautions, given the risk to perform the 
examination in COVID-19 patients.7
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Management of Cardiovascular Complications 
during Hospitalization for COVID-19 
In regards to reduce the burden of possible chronic 
cardiomyopathy after an episode of acute COVID-19 
requiring hospitalization, maximal therapy should be 
given for those showing signs of cardiac complications. 
Management of patients with COVID-19 have been 
described extensively in many reviews recently. 7,12,13 For 
severe COVID-19 with possible cardiac involvement 
optimal supportive care is very important. These include:
- Volume status and fluid resuscitation should be 
performed cautiously to avoid increase load in 
possible cardiomyopathy patients
- Maintaning targeted MAP by using proper 
inotropics if necessary
- Mechanical support /ECMO might be required in 
those with failing heart such as those with acute 
cardiomyopathy.13
In patients with acute cardiomyopathy in COVID-19 
the severe symptoms usually happen during inflammatory 
period or interleukin storm. Optimal antiinflammatory 
and antiviral including hydroxychloroquine 
and azithromycin, anti-inflammatory therapies such 
as intravenous immune globulin (IVIG), tocilizumab, 
anakinra, and IV steroids. Antiviral therapy may 
include: remdesivir, lopinavir and ritonavir, have been 
used or considered in patients with COVID-19. 12,14 
Caution should be given when using chroroquin since it 
may prolong QT interval, thus ECG evaluation should 
be performed in those receiving the drugs.
Use  of  ACE  inhibitor  and  ARB has  been  a 
controversial  issues  given ACE-2 receptor known as entry 
site for coronavirus infection. A newest retrospective 
analysis in 1128 COVID-19 patients using ACE inhibitor 
and ARB concluded that in hospitalized COVID-19 
patients with hypertension, use of ACEI/ARB lowering 
risk of all-cause mortality compared with ACEI/ARB 
non-users. While study interpretation needs to consider 
the potential for residual confounders. But the use 
ACE inhibitor should be balanced with hemodynamic 
and vital signs especially those in intensive care.15 
Prevention
Since patients with underlying cardiovascular 
disease are at higher risk of morbidity and mortality, 
those patients should take great care in preventing of 
possible re-infection. That would increase the rate for 
possible cardiomyopathy development. This includes 
frequent handwashing, social distancing measures, 
proper and appropriate use of masks and cleaning and 
disinfecting commonly touched surfaces. If possible, 
the survivor patient should reduce outpatient visit and 
convert to telehealth visits to minimize risk of acquiring 
an infection in the nosocomial setting.6 
Among those who survive from COVID-19. optimal 
medical therapy should be continued along with social 
distancing and personal hygiene. Given the newest 
study on the benefit of use ACE inhibitor and ARB in 
COVID-19 patients especially those with hypertension, 
it might be great hope that its benefit may be extended 
also to preserve cardiac function in cardiomyopathy 
post COVID-19 hospital care. However further study 
should be needed to resolve this issues.
Summary
Patients with COVID-19 may develop myocardial 
injury or myocarditis that lead to cardiomyopathy as the 
chronic sequelae of the disease. There are various possible 
mechanisms for the development of cardiomypathy after 
hospital care in patients recover from COVID-19. It is 
important to pay attention to this survivor group since 
the pandemic may be lasting for longer period. Optimal 
medical treatment and comprehensive prevention should 
be taken to manage those high risk patients of having 
cardiomyopathy during hospitalization as well as later 
at post-discharge period. These includes: providing best 
available COVID-19 drugs, cardiovascular medications 
and treatments, and other social preventive measures.
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